Close Menu

This article has been updated from a previous version to include comments made by Bruker executives during the company's earnings call.

NEW YORK – Bruker on Tuesday reported that its preliminary fourth quarter Q4 revenues were up 8 percent year over year.

For the three months ended Dec. 31, the company reported revenues of $599.9 million, up from $553.6 million in Q4 2018, and beating the consensus Wall Street estimate of $576.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.